January 22, 2019

Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDA

Capricor Therapeutics announced that it had positive outcomes in its comprehensive multidisciplinary meeting with the FDA regarding development of the company’s novel cell therapy candidate, CAP-1002, after being placed on voluntary hold last month. To…

Learn More

December 17, 2018

End Duchenne Tour Recap: Cincinnati, OH

PPMD headed to Cincinnati, OH for our End Duchenne Tour stop on November 17, 2018. Many families and members of the Duchenne community came together to learn about the latest information and resources for Duchenne families. PPMD…

Learn More

November 29, 2018

End Duchenne Tour Recap: Palo Alto, CA

PPMD headed to Palo Alto, CA for our End Duchenne Tour stop on November 3, 2018. Many families and members of the Duchenne community came together to learn about the latest information and resources for Duchenne families….

Learn More

July 24, 2018

WATCH: HOPE-2 Duchenne Clinical Trial – Webinar Recording with Capricor

Capricor Therapeutics recently joined PPMD for a community webinar update to discuss the HOPE-2 trial. During the webinar, Capricor provided a background of CAP-1002 and its clinical development to date that has led to the…

Learn More